Medtronic (MDT)
NYSEHealth CareMedical DevicesSnapshot 2026-07-07
$83.84+0.94%
Close 2026-07-07 · 1-day change
Reading MDT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MDT free→NYSEHealth CareMedical DevicesSnapshot 2026-07-07
Reading MDT? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MDT free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on consistent revenue and earnings growth. The current thesis state is stable, supported by management's commitment to key growth areas and recent strong financial results.
The market currently prices MDT as relatively cheap compared to its peers, with a slight expectations gap indicating that some positive developments may not be fully reflected. The valuation has recently fallen, suggesting that the market may be cautious but not overly pessimistic.
Fundamentals are likely to show continued organic revenue growth, as management has guided for an acceleration in growth rates. While there is a low miss probability, recent industry trends raise some caution due to peers experiencing earnings misses.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and BSX. If these companies continue to perform well, MDT could benefit from positive sector momentum; however, any negative guidance from these peers could pose risks.
Overall, MDT's multi-year view is supported by strong management execution and recent financial performance. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Medtronic maintained and raised its non-GAAP EPS guidance. This supports the company's growth in key franchises and new product launches. However, the latest earnings miss and a cyberattack notification challenge its regulatory compliance.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This growth rate is a key indicator of Medtronic's performance and market strength. A miss could signal weakening demand.
Confirms:Q1 FY27 organic revenue growth reported below 6.75%.
Disproves:Q1 FY27 organic revenue growth reported above 7.25%.
Why it matters: Achieving growth is crucial for Medtronic's long-term success. Results will indicate business health.
Confirms:Organic revenue growth reported above 5% for FY26.
Disproves:Organic revenue growth reported below 0% for FY26.
Why it matters: The result will affect Medtronic's reputation. It will also impact how the company runs.
Confirms:A public statement says there are no new data breaches. Operations are not affected.
Disproves:New findings show serious data breaches. These affect operations and patient safety.
Why it matters: Earnings results will show how Medtronic is doing. They will also show growth trends.
Confirms one read:Earnings results show revenue growth over 6.75% compared to last year.
Confirms the other:Earnings results show revenue growth under 6.75% compared to last year.
Why it matters: Keeping EPS guidance shows the company is stable. It shows confidence in earnings.
Confirms:Non-GAAP EPS guidance remains unchanged or is raised for FY26.
Disproves:Non-GAAP EPS guidance is lowered for FY26.
Why it matters: This approval shows Medtronic's progress in robotic surgery. It may help gain market share.
Confirms:The FDA approved Hugo™ RAS for general surgery.
Disproves:FDA denies Hugo™ RAS for general surgery.
Why it matters: Fixing the IT security breach is important. It helps restore trust and protect data.
Confirms:A public announcement will explain how they fixed the IT security breach.
Disproves:New information about the breach shows there are still problems.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Changes in leadership can change company plans and results. Stability is important.
Confirms one read:Dr. Kweli Thompson announced positive changes after starting his role.
Confirms the other:There may be a negative effect on company results after the change.